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ABSTRACT
Hypophosphatasia (HPP) is an inherited systemic skeletal disease caused by mutations in the gene encoding the tissue-nonspecific
alkaline phosphatase (TNALP) isozyme. The clinical severity of HPP varies widely, with symptoms including rickets and osteomalacia.
TNALP knockout (Akp2
 / ) mice phenotypically mimic the severe infantile form of HPP; that is, TNALP-deficient mice are born with a
normalappearancebutdieby20daysofageowingtogrowth failure,hypomineralization,andepilepticseizures.Inthisstudy, alentiviral
vector expressing a bone-targeted form of TNALP was injected into the jugular vein of newborn Akp2
 /  mice. We found that alkaline
phosphataseactivityinthe plasmaoftreatedAkp2
 / miceincreasedandremained athighlevelsthroughout thelifeoftheanimals. The
treated Akp2
 /  mice survived for more than 10 months and demonstrated normal physical activity and a healthy appearance. Epileptic
seizures were completely inhibited in the treated Akp2
 /  mice, and X-ray examination of the skeleton showed that mineralization was
significantly improved by the gene therapy. These results show that severe infantile HPP in TNALP knockout mice can be treated with a
single injection of lentiviral vector during the neonatal period.  2011 American Society for Bone and Mineral Research.
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Introduction
H
ypophosphatasia (HPP) is an inherited skeletal disease
caused by mutations in the gene encoding the tissue-
nonspecific alkaline phosphatase (TNALP) isozyme.
(1) The symp-
toms of HPP include hypomineralization that causes rickets in
infants and children and osteomalacia in adults.
(2,3) The clinical
severity of HPP varies widely from a lethal perinatal form to mild
odontohypophosphatasia that manifests only dental abnormal-
ities.
(4) In the infantile form, postnatal development appears to
proceed normally before the onset of failure to thrive and the
associated development of rickets before 6 months of age.
Severe infantile HPP is often fatal.
(3)
TNALP is an ectoenzyme that is attached to the outer plasma
membrane via a glycosylphosphatidylinositol (GPI) anchor.
(5,6)
AbsenceofTNALPactivityresultsinextracellularaccumulationof
natural substrates such as inorganic pyrophosphate (PPi),
(7,8)
pyridoxal 5’-phosphate (PLP),
(9,10) and phosphoethanolamine
(PEA).
(11) Since high concentrations of PPi result in a strong
inhibition of hydroxylapatite crystal growth, normal mineraliza-
tion of the systemic bones and teeth is impaired in HPP
patients.
(8,12) Pyridoxine-responsive seizures are also observed in
some severe cases. Enzyme-replacement therapy using various
types of alkaline phosphatase
(13–17) and cell therapy using bone
marrow cells
(18,19) and mesenchymalcells
(20) havebeen reported
with no or very limited clinical benefit.
TNALP knockout mice have been established in two in-
dependent laboratories.
(21,22) These mice are born with a normal
appearance but, owing to deficient degradation of PPi and
abnormal metabolism of PLP, develop rickets and die by 20 days
of age as a result of severe skeletal hypomineralization and
epileptic seizures and represent an appropriate model of the
infantile form of HPP.
(23,24) Recently, Milla ´n and colleagues
(25)
treated TNALP knockout mice with a daily subcutaneous
injection of a bone-targeted form of TNALP in which a bone-
targeting deca-aspartate sequence was linked to the C-terminal
end of soluble TNALP.
(26,27) Based on those data, clinical trials
of enzyme-replacement therapy with bone-targeted TNALP in
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135patients with adult and infantile HPP have been initiated.
(28) A
limitation of enzyme-replacement therapy for HPP is the
restricted half-life of the TNALP protein in patients’ fluids and
tissues, which necessitates repeated administration of large
amounts of the enzyme for long-term correction.
In this study, we examined viral vector–mediated gene
therapy of HPP. We found that a single injection of lentiviral
vector expressing bone-targeted TNALP into neonatal HPP mice
resulted in long-term high levels of ALP in the serum and long-
term phenotypic correction in HPP mice. We conclude that gene
therapy may prove to be an important option for the treatment
of human HPP.
Materials and Methods
Plasmid construction
To create TNALP-D10 cDNA coding for TNALP lacking the GPI
anchor sequence and containing 10 repeated aspartic acid (Asp)
residues at its C-terminus, polymerase chain reaction (PCR) was
performed using primers TNALP-D10-f (5’-GAA TTC ACC CAC GTC
GAT TGC ATC TCT CTG GGC TCC AG) and TNALP-D10-r (5’-GAA
TTC TCA GTC GTC ATC ATC ATC ATC GTC GTC ATC GTC GTC GCC
TGC GGA GCT GGC AGG AGC ACA GTG-3’) with pcDNA3 TNALP
cDNA plasmid as the template.
(29) The PCR product then was
digested with EcoRI and inserted into the pGEM T-easy vector
(Promega Corporation, Madison, WI, USA). A second PCR was
performed using primers EcoRI–TNALP-f (5’-TTT GAA TTC GCC
ACC ATG ATT TCA CCA TTC TTA GTA C-3’) and TNALP-D10-NotI-r
(5’-TTT GCG GCC GCT CAG TCG TCA TCA TCA TCA TCG). The
orientation of each sequence then was confirmed.
The pHIV-TNALP-D10 plasmid was constructed by insertion of
theEcoRIandNotIfragmentscontainingthecDNAforTNALP-D10
into pC1(–)3UTR-del, which is a newly constructed SJ1-based
HIV-1 vector containing 0.25-kb insulators in the U3 and the
murine stem cell virus (MSCV) long terminal repeat (LTR) as an
internal promoter (Fig. 1A).
(30)
Lentiviral vector preparation
Lentiviral vector was prepared by transient transfection in 293T
cells, as described previously.
(30) Vector preparation treated with
Benzonase (50mL/mL) for 1 hour at room temperature was
filtrated by 0.45-mm membrane after adjustment of the pH to 8.0
with 1N NaOH. Vector was concentrated using Acrodisc Units
with Mustang Q Membranes (PALL Corporation, Ann Arbor, MI,
USA).
(31,32) The eluted solution containing lentiviral vector was
ultracentrifuged with a 20% (w/v) sucrose underlay for purifi-
cation, and the infectious vector particle (titer) was determined
in HeLa cells. The titer was expressed as transducing units per
milliliter (TU/mL).
Animal procedures and experiments
All animal experiments were preapproved by the Nippon
Medical School Animal Ethics Committee. Wild-type (WT)
Akp2
þ/  heterozygous (HET) and Akp2
 /  knockout (HPP) mice
were obtained by mating Akp2
þ/  heterozygous mice with mice
of a mixed 129J C57Bl/6J genetic background.
(22) Lentiviral
vector (5.0 10
7 TU/100mL in PBS) was injected into the jugular
vein of neonatal mice on days 1 through 3. Breeding HET pairs
were fed modified Laboratory Rodent Diet 5001 (Purina Mills, St
Louis, MO, USA)
(35) composed of CMF laboratory feed (Oriental
Yeast Co., Ltd., Tokyo, Japan) supplemented with 325ppm
pyridoxine/10kg of feed.
ALP activity
Blood samples were collected from the tail vein or the orbital
sinus. The level of ALP in the plasma was quantified using a
colorimetric assay for ALP activity, as described previously.
(36)
ALP activity was determined using 10mM p-nitrophenyl phos-
phate (Sigma-Aldrich, Steinheim, UK) as the substrate in 100mM
2-amino-2-methyl-1,3-propanediol-HCl buffer containing 5mM
MgCl2 (pH 10.0) at 378C. ALP enzyme activity was described in
units (U) defined as the amount of enzyme needed to catalyze
production of 1mmol of p-nitrophenol formed per minute. ALP
activity in plasma was calculated as units per milliliter (U/mL).
Biodistribution of lentiviral vector
Mice were deepley anesthesized and perfused with 15mL of PBS
containing 150 U of heparin and 15mL of PBS. The liver, spleen,
kidney, lung, heart, and bone (femur) were harvested, and
homogenates were made using the Percellys-24 bead-beating
homogenizer according to the company’s protocol (Bertin
Technologies, Paris, France). Genomic DNA was extracted from
tissue homogenates using the Gentra Puregene Kit (Qiagen
Siences, Germantown, MD, USA) and was subjected to real-time
PCR to estimate the distribution. The primer/probe sets FPLV2
(modified at one base to 5’-ACT TGA AAG CGA AAG GGA AAC-3’
owing to a difference in the HIV-1 strain), RPLV2 (5’-CAC CCA TCT
CTC TCC TTC TAG CC-3’), and LV2 (5’-AGC TCT CTC GAC GCA GGA
CTC GGC -3’) were used to detect the lentiviral vector provirus,
as described previously.
(33) TaqMan ribosomal RNA control re-
agents (Applied Biosystems, Branchburg, NJ, USA) were used to
quantify the amount of genomic DNA. To estimate vector distri-
bution, genomic DNA extracted from the bone marrow cells of
BL/6 wild-type mice or genomic DNA spiked with plasmid DNA
was used as a standard, and average copy number per diploid
were determined.
(34)
X-ray analysis
Digital microradiography images were obtained using a mFX-
1000 (Fujifilm, Tokyo, Japan) and imaged with FLA-7000
(Fujifilm). The X-ray energy levels were 25kV and 100 mA, and
an exposure time of 90seconds was used for 15-day-old mice,
and 15seconds was used for adult mice. We examined a mini-
mum of three X-ray pictures from each group at given ages.
ALP activity staining
Bone samples were fixed in neutral buffered formalin for
24hours at 48C. Knuckle samples then were decalcified in 10%
EDTAsolutionwithrotationfor2to3daysat48C.Fortheazo-dye
method, knuckles were embedded in optimal-cutting-tempera-
ture (OCT) compound (Tissue-Tek, SAKUSA Finetechnical, Tokyo,
Japan) and sectioned using a Leica CM1950 cryostat. Thin
sections (4mm thick) were air-dried for 10minutes, washed in
136 Journal of Bone and Mineral Research YAMAMOTO ET AL.Fig. 1. Lentiviral-mediated gene therapy of Akp2
 /  hypophosphatasic (HPP) mice. (A) Schematic diagram of HIV-TNALP-D10 lentiviral vector. LTR¼long
terminal repeat; MSCVU3¼U3 region of the LTR promoter of murine stem cell virus; WPRE¼woodchuck hepatitis virus posttranscriptional regulatory
element; INS¼chicken b-globin hypersensitivity site 4 insulator; cppt-cts¼central polypurine tract–central termination sequence; RRE¼reverse
responsive element. (B) Growth curves of untreated HPP mice (n¼7), treated HPP mice (n¼6), and WT (n¼4) and HET (n¼9) mice. The body weights
of untreated HPP mice were recorded until spontaneous death. The weights of WT and HET (total n¼13) mice are presented as the average SD. (C) The
comparison of average body weights of treated HPP mice (male, n¼3; female, n¼3) and WT/HET littermates (male, n¼8; female, n¼8 to 10).
 p<.05;
   p<.001.(D)Thesurvivalcurvesoftreated(n¼7)anduntreated(n¼12)HPPmice.(E) ConcentrationofplasmaALPinthetreated(n¼6)anduntreated
(n¼5) HPP mice and HET (n¼15 to 21) and WT (n¼6-9) controls.
  p<.01 versus the WT group;
   p<.001 versus the WT group. ( F) Distribution of
lentiviral vector. The copy numbers of the vector genome in the organs was determined by qPCR with HIV-TNALP-D10 injected WT mice. Data are
presented as mean SEM (n¼4).
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maleic acid buffer (pH 7.4) for 30minutes for the reactivation of
ALP.
(37) The sections then were incubated in a freshly prepared
mixture of Naphthol AS-MX phosphate disodium salt (Sigma-
Aldrich) and Fast Blue BB Salt (Sigma-Aldrich) as described
previously.
(38) Methyl green served as the counterstain.
Statistical analysis
Data are expressed as mean SD. Differences between two
groups were tested for statistical significance using Student’s
t test. p values<.05 were considered statistically significant.
Kaplan-Meier curves were produced and analyzed using SPSS for
Windows, Version 14.0J (SPSS Japan, Tokyo, Japan).
Results
Growth and survival of Akp2
 /  mice
The growth of the Akp2
þ/  HET mice appeared indistinguishable
from that of the WT mice. The Akp2
 /  HPP mice were born with
a normal appearance and weight. However, HPP mice showed
apparent growth failure and became progressively exhausted
(Fig. 1B). Most of the HPP mice also developed spontaneous
seizures with various clinical presentations, including tonic-
clonic convulsions and abnormal running and vocalization. The
mice usually died 1 to 2 days after the epileptic seizures began.
The average life span of the HPP mice was 12.0 4.4 days
(n¼13). Pyridoxine supplementation of the food for the nursing
motherdelayedtheonsetoftheepilepticattacksintheneonates
and extended their survival to postnatal day 18.1 7.6 (n¼15).
Lentiviral vector containing bone-targeted human TNALP
cDNA (HIV-TNALP-D10) was injected into the jugular vein of the
neonatal HPP mice on days 1 through 3 (n¼6). The weight and
growth rates of the treated HPP mice were improved compared
with the untreated HPP mice and were indistinguishable from
those of their WT and HET littermates (n¼13; Fig. 1B). The long-
term follow-up was done for 7 treated mice. Compared with
untreated mice (n¼12), the life spans of treated mice (n¼7)
weresignificantly extended uptoatleast160 days ofage, except
that one treated animal died on day 6 from unknown causes
(Fig. 1D). In the long survivors (n¼6), 3 were euthanized on
day 160 for X-ray analysis, whereas the remaining 3 animals
survived for more than 400 days with normal appearance and
physical activity. Seizures were not observed in the treated mice
throughout the experimental period. The average body weights
of treated HPP (n¼6) and WT/HET (n¼13 to 18) were compared
on days 1, 10, 30, 60, and 160 (Fig. 1C). The body weights differed
between male and female mice after 60 days. In either gender,
the slight but significant growth retardation was detected in
treated HPP mice on days 60 and 160.
Lentivirus-mediated expression of ALP
At 10 to 12 days after birth, ALP activity in the plasma of WT and
HET mice was 0.25 0.07 U/mL (n¼9) and 0.16 0.05 U/mL
(n¼21), respectively, whereasthat ofthe HPPmicewasless than
0.1 U/mL(n¼5; Fig. 1E).A singleinjection ofHIV-TNALP-D10 into
the neonatal HPP mice (n¼6) on days 1 through 3 resulted in
extremely high levels of plasma ALP (2.67 0.56 U/mL). The
plasma ALP activity in the WT and HET mice decreased slowly
with aging, whereas the lentivirus-mediated expression of ALP
remained stable, and the high levels of ALP activity persisted for
at least 6 months. At 60 days of age, the average ALP activity in
the treated HPP mice was 73-fold higher than that of the WT
mice (5.14 2.66 versus 0.07 0.02).
Biodistribution of lentiviral vector was determined using
quantitative PCR (qPCR) on genomic DNA isolated from the
injected WT littermate mice 14 days after injection (Fig. 1F). The
highest copy number of integrated vector was detected in liver
samples (0.40 copy/diploid). Low levels of lentiviral integration
also were observed in the spleen and the heart. Transduction of
the bone tissue, including bone marrow cells, was very low
(<0.001 copy/diploid).
Radiographic analysis
Since radiographic changes in the HPP mice were not apparent
during the first 8 days of life, we examined X-ray images of
thefeetandlegsofmiceatapproximately20daysafterbirth.The
severity of the mineralization defects in the untreated HPP mice
was found to be highly variable. In the most severely affected
cases,themetacarpalanddigitalbonesweresignificantlyshorter
than those of the WT mice, and their epiphyses were not
detected. In addition, some of the carpal bones were absent.
We also observed the absence of secondary ossification centers
in the feet (Fig. 2). The most severe phenotype was observed in
approximately 10% of the Akp2
 /  homozygous neonates, and
thesemiceusuallydiedby10daysofage.Inthemildercases,the
epiphyses and all the digital bones were significantly miner-
alized, even though the HPP mice were smaller than the HET and
WT mice. Heterogeneous radiographic changes between these
two extreme phenotypes were observed in the untreated HPP
mice.
X-ray images of treated HPP mice showed that mineralization
was accelerated following lentivirus-mediated expression of
TNALP-D10. Secondary ossification centers were detected in
the feet of all treated animals at 15 days of age, although the
intensity of the mineralization was variable. Ossification of
the carpal bones also was improved. All the untreated HPP mice
died, with an average survival of 18.1 days. No differences in
skeletal structure and mineralization were observed between
thelongsurvivorsaftertreatmentandtheWTmiceat100daysof
age. These results indicate that mineralization defects in HPP
mice can be corrected efficiently by gene therapy.
Histochemical examination of the bone
The proximal tibias were analyzed histochemically for ALP
activity using the azo-dye technique with methyl green counter-
staining (Fig. 3). Strong ALP activity was detected in both the
bone and hypertrophic cartilage zones of the WT mice (Fig. 3A),
whereas no ALP signal was observed in the epiphysis of the HPP
mice (Fig. 3B). After treatment with lentiviral vector, faint ALP
staining was observed on the surface of the endosteal bone
(Fig. 3C, D).
138 Journal of Bone and Mineral Research YAMAMOTO ET AL.Fig. 2. X-ray images of the feet. Secondary ossification centers in the hind paws were absent in untreated HPP mice but were detectable in the treated
mice at 18 days after birth. No differences in skeletal mineralization were observed between treated long survivors and WT mice at 100 days of age.
Fig. 3. Histochemical staining of ALP activity in the tibias. ALP activity was detected in WT (A) but not HPP mice (B) at 15 days after birth. Following
treatmentwithlentiviralvector,(C)ALPactivitywasdetectedonthesurfaceoftheendostealboneat18daysafterbirth.(D)Magnifiedimageofthesquare
in panel C. Bars¼1mm.
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TNALP is an ectoenzyme that is known to be particularly
abundant on the cell surfaces of osteoblasts and hypertrophic
chondrocytes, including their shed matrix vesicles.
(6,39) Since ALP
functions on the exterior of the cell, enzyme replacement
following repeated administration of soluble ALP has been
hypothesized as a potential approach to treat ALP deficiencies.
However, the outcomes of previous clinical trials of enzyme-
replacement therapy have proven disappointing. Intravenous
infusions of ALP-rich serum from patients with Paget dis-
ease
(13,14) and purified soluble ALP from human liver
(16) and
placenta
(17) have shown no significant clinical benefits in
patients with HPP. Recently, Milla ´n and colleagues
(25) demon-
strated that daily injections of high-dose bone-targeted
TNALP significantly extended the lifespan and corrected the
abnormal phenotypes of HPP mice, suggesting that HPP
could be treated by enzyme replacement if sufficient
amounts of TNALP were able to reach the sites of skeletal
mineralization. Based on these data, new clinical trials involving
enzyme-replacement therapy for HPP patients have been
initiated.
(28)
A general problem of enzyme-replacement therapy is the
short half-life of the administered protein in patients. A
pharmacokinetic study showed that the half-life of bone-
targeted TNALP is 34hours in the plasma of adult mice, but in
bone tissue the half-life is extended to more than 300hours.
(25)
Nevertheless, repeated administration of large amounts of the
enzyme is required for long-term correction. In the initial clinical
trials, HPP patients received subcutaneous injections of bone-
targeted TNALP three times weekly.
(28) The preparation of
adequate amounts of clinical-grade purified enzyme is a
limitation, and repeated injection is highly invasive and not
optimal for small children. In this study we demonstrated that a
single injection of lentiviral vector resulted in sustained
expression of ALP and phenotypic correction in HPP neonatal
mice. As such, viral vector–mediated enzyme replacement may
prove to be more practical than classic enzyme replacement by
repeated injection.
One of the concerns of gene therapy is the safety of the viral
vector. We used an HIV-1-based lentiviral vector in this study.
(30)
Lentivirus-mediated gene transfer has proven to be effective
for long-term expression of transgenes in nondividing cells.
Although the pathogenicity of HIV-1 was almost negligible in
the current modified version of lentiviral vector, insertional
mutagenesis is still a major concern for all integrating vectors.
(40)
To minimize the possibility of protooncogene activation, our
novel self-inactivating lentiviral vector contains the insulator
element from the chicken b-globin locus.
(30) So far, lympho-
proliferative complications owing to insertional mutagenesis
have been detected in ex vivo hematopoietic stem cell gene
therapy only. For the treatment of HPP, lentiviral vector
was injected directly into the circulation of neonatal mice.
After this in vivo systemic gene therapy, the lentiviral sequence
was detected in the liver, lung, and heart. The oncogenicity of
the integrated lentiviral vector in these differentiated tissues
requires further examination in a long-term follow-up
study.
We also found that the epileptic seizures were completely
inhibited and the lifespan was significantly extended in the
treated HPP mice. Without treatment, HPP mice died by 20 days
of age.
(22,35) The major cause of death in the untreated HPP mice
was apnea, most likely resulting from their severe epileptic
convulsions.
(21) Pyridoxine-responsive seizures in HPP patients
and HPP model mice are thought to be caused by reduced levels
of the inhibitory neurotransmitter g-aminobutyric acid (GABA) in
the brain.
(21,35) PLP is an essential cofactor of glutamate
decarboxylase, which is responsible for the synthesis of GABA.
(41)
Diminished hydrolysis of extracellular PLP in HPP causes
decreased intracellular pyridoxal levels in cells. This results in
a reduction in the rephosphorylation of pyridoxal to PLP, and
thus biosynthesis of GABA within the brain cells is reduced.
(10)
The seizure phenotype can be rescued in part by administration
of pyridoxal.
(23) We demonstrated that epileptic seizures were
efficiently inhibited by either systemic infusion of TNALP
(25) or
viral vector–mediated expression of TNALP, suggesting that the
defective metabolism of PLP in the brain could be corrected by
replacement of soluble TNALP.
Although epileptic seizures are observed in some severely
affected patients, the major clinical complications in human
HPP patients are directly related to defective skeletal miner-
alization.
(3) Patients with severe infantile HPP usually die from
respiratory failure caused by skeletal diseases in the chest, such
as flail chest, rachitic deformity, and rib fractures.
(3) Compared
with severe infantile HPP in human patients, bone defects in our
mouse model are relatively mild. The Akp2
 /  HPP mice were
born with a normal appearance and bone mineral deposition.
Hypomineralization becomes apparent after around 10 days
of age, although the severity of mineralization defects varies
widely.
(22) Lentivirus-mediated expression of bone-targeted ALP
efficiently prevents the progressive skeletal demineralization, as
well as the lethal epilepsy.
Since enzyme replacement also was effective,
(25) the major
mechanism of successful gene therapy for HPP mice seems to be
due to continuous supply of bone-targeted TNALP from the
vector-infected liver to the circulation. Another possibility is that
osteoblasts and chondrocytes may be directly transduced with
lentiviral vector. However, since the copy number of integrated
vector in the whole bone tissue was very low, the ALP staining in
treated mice is mainly due to the circulating TNALP-D10 in the
bone matrix. The contribution of in situ expression of TNALP in
bone cells to bone mineralization is not likely to be significant.
A major physiologic role for TNALP has been shown to be the
restriction of the extracellular pool of PPi, which is a strong
inhibitor for mineralization.
(24,39) Localization of TNALP to the
skeleton should be important for the treatment of HPP. TNALP
with a repetitive C-terminal extension of 10 Asp was shown to
display high affinity for bone tissue both in vitro
(26) and in
vivo.
(25) The use of the bone-targeted TNALP construct in a
clinical setting is currently under investigation in clinical trials.
(28)
The efficacy of gene therapy to correct hypomineralization
was evaluated by radiographic examination. The major problem
is that the severity of the mineralization defects in untreated
infantile Akp2
 /  mice is highly variable. In addition, X-rays of
infantile mice could be taken only after euthanization. The time
course of mineralization in a single animal could not be
140 Journal of Bone and Mineral Research YAMAMOTO ET AL.examined under the condition used. Further studies using more
reliable histomorphometric and micro–computed tomographic
(mCT) techniques may be required to optimize the gene therapy
protocol to rescue the skeletal phenotype.
In conclusion, we found that severe infantile HPP in TNALP
knockout mice can be treated with a single injection of lentiviral
vector during the neonatal period. Lentiviral-mediated gene
therapy may prove to be an important option in the treatment of
human hypophosphatasia.
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